This is a list of all the questions and their associated study carrel identifiers. One can learn a lot of the "aboutness" of a text simply by reading the questions.
| identifier | question |
|---|---|
| cord-257533-i85dyg8n | What are the Underlying Transmission Patterns of COVID-19 Outbreak? |
| cord-277355-si3g5dih | Do deletions in CP also affect flaviviral virulence in vivo? |
| cord-271153-c0aw6jkz | The public health emergency management system in China: trends from Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore Coronavirus Resource Center Early response to the emergence of influenza A( H7N9) virus in humans in China: the central role of prompt information sharing and public communication COVID-19: too little, too late? |
| cord-288038-jdinf8od | WHO| Data, statistics and graphics| Vaccine Introduction slides Could enhanced influenza and pneumococcal vaccination programs help limit the potential damage from SARS- CoV-2 to fragile health systems of southern hemisphere countries this winter? |
| cord-269448-1jikrn37 | Is it time to change strategies? |
| cord-299952-xvtt8fz8 | alfa-2a Could preventive intranasal interferon lower the morbidity in children prone to respiratory illness? |
| cord-276907-b855tj7x | Procedure for assessing the acceptability, in principle, of vaccines for purchase by United Nations agencies Tackling drug resistant infections globally: Final report and recommendation How can vaccines contribute to solving the antimicrobial resistance problem? |
| cord-282764-d9x1wii6 | The main question is why did the major glycosylation form of S TR2 protein lie in ∼115 kDa instead of ∼130 kDa? |
| cord-256784-wfaqim7d | Distinct immune response in two MERS- CoV- infected patients: can we go from bench to bedside? |
| cord-283475-28900qlr | The cost structure of routine infant immunization services: a systematic analysis of six countries Can thermostable vaccines help address cold- chain challenges? |
| cord-301601-4vkag60z | The phosphoprotein of attenuated measles AIK- C vaccine strain contributes to its temperature- sensitive phenotype Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? |
| cord-310249-cvv77f10 | Can a commercial vaccine protect pups against a recent field isolate of parvovirus? |
| cord-310249-cvv77f10 | Elevated clinical scores were observed beginning day 4 and peaked( mean 12.25* 4.91) on day 7 post- challenge( Figure,? |
| cord-293234-ouykx6g5 | What does the odds ratio estimate in a case- control study? |
| cord-293234-ouykx6g5 | preliminary mid- season effectiveness estimates: reason for concern, confounding or are we following the right track? |
| cord-307939-rydgncys | The survey was carried out using a self- administered, anonymous questionnaire, which consisted of four sections:( 1) Demographics information( gender, age, educational level, employment status, living area and number of children within the family);( 2) Have you ever heard of avian influenza A( H7N9)? |
| cord-307939-rydgncys | Why do I need it? |
| cord-282314-9cua2jzg | Non- coding C? |
| cord-279364-j93f6eso | : What is the effect of priming? |
| cord-279364-j93f6eso | A prospective randomized controlled trial Effect of a hospital campaign for influenza vaccination of healthcare workers Use of a mobile cart influenza program for vaccination of hospital employees Discrete choice experiments in health care Are Healthcare Choices Predictable? |
| cord-279364-j93f6eso | What influenza vaccination programmes are preferred by healthcare personnel? |
| cord-289090-7x2752j4 | Can acute otitis media caused by Haemophilus influenzae be distinguished from that caused by Streptococcus pneumoniae? |
| cord-289090-7x2752j4 | Is bilateral acute otitis media clinically different than unilateral acute otitis media? |
| cord-289090-7x2752j4 | diagnosis and management in the year 2000 Complications of acute otitis media in children in southern Finland National differences in incidence of acute mastoiditis: relationship to prescribing patterns of antibiotics for acute otitis media? |
| cord-259299-z3o4t7mz | A vaccine based on stably attenuated FMDV could provide improved safety over the existing product?. |
| cord-259299-z3o4t7mz | Subcutaneous inoculation in cattle induced neutralizing antibody titers( PRN,,,) of 2.0, 2.6 and 2.9 and the animal with the highest titer( 2.9) was protected against challenge, the animal with the PRNTO 2.6 developed a fever but no pedal lesions, and the third animal( PRN,"2.0) developed fever and mild lesion?. |
| cord-259299-z3o4t7mz | The results of this study, in conjunction with our previous result? |
| cord-304807-j2k1oel2 | Inactivated or damaged? |
| cord-296469-h0ma163u | Given the health, social and economic impact of infectious diseases with pandemic potential, there has been much attention to these microbial threats and, not surprisingly, the first question is always,''Is there a vaccine? |
| cord-296469-h0ma163u | How to deal with vaccine hesitancy? |
| cord-279985-de0b27nq | Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40 ligand Is cancer dangerous to the immune system? |
| cord-279985-de0b27nq | Vaccine- induced CD8+ central memory T cells in protection from simian AIDS Effector cytotoxic T lymphocyte numbers induced by vaccination should exceed levels in chronic infection for protection from HIV HIV- specific CD4+ T cells and viremia: who's in control? |
| cord-281676-yy5etfek | Cytotoxic T lymphocyte- associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation Regulatory T cells: how do they suppress immune responses? |
| cord-281676-yy5etfek | The level of virus- specific T- cell and macrophage recruitment in porcine reproductive and respiratory syndrome virus infection in pigs is independent of virus load Effect of genotypic and biotypic differences among PRRS viruses on the serologic assessment of pigs for virus infection Efficacy of a modified live porcine reproductive and respiratory syndrome virus( PRRSV) vaccine in pigs naturally exposed to a heterologous European( Italian cluster) field strain: clinical protection and cell- mediated immunity Challenges for porcine reproductive and respiratory syndrome virus( PRRSV) vaccinology Delivery systems: a vaccine strategy for overcoming mucosal tolerance? |
| cord-271734-1cfhjuxi | BCG Vaccination Induce Protective Trained Immunity for SARS- CoV-2? |
| cord-271734-1cfhjuxi | Why Children Fare Better than Adults? |
| cord-294789-07hto8qn | People will judge a COVID-19 vaccination campaign's integrity not simply on biomedical merits, but on matters of fairness and equity- that is, have people received their just portion of health services, and has disease prevention, ultimately, been fairly distributed? |
| cord-294789-07hto8qn | Will Ebola change the game? |
| cord-273526-ah0dvnxv | Two years after pandemic influenza A/2009/ H1N1: what have we learned? |
| cord-324911-6s7ubbxl | Alongside these efforts, the UK Chief Medical Officer for the Department of Health and Social Care( DHSC), Dame Sally Davies, raised the question to government and related stakeholders-what could the UK do to be better prepared for future outbreaks of infectious diseases? |
| cord-255734-038xu4hq | Can the virus establish persistent infection and can humans be repeatedly infected? |
| cord-255734-038xu4hq | Finally, if SARS fails to return, how will vaccine manufacturers test candidate vaccines for efficacy? |
| cord-255734-038xu4hq | If we define the ability of the virus to replicate in monocytes/ macrophages can we be assured that antibody- dependent enhancement will not be a problem for a SARS vaccine? |
| cord-255734-038xu4hq | What are the viral virulence factors and can we use this information to develop an attenuated strain? |
| cord-255734-038xu4hq | What is the role of lymphocytic infiltrates and do alveolar macrophages enhance disease or control infection? |
| cord-303200-hwvkvdlk | A canine parvovirus mutant is spreading in Italy Surveillance activity for canine parvovirus in Italy Canine parvovirus infection: which diagnostic test for virus? |
| cord-341626-04svm6le | The use of health economics to guide drug development decisions: determining optimal values for an RSV- vaccine in a model- based scenario- analytic approach Hospitalization for respiratory syncytial virus infection in young children: development of a clinical prediction rule Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk Mortality in children from influenza and respiratory syncytial virus Respiratory syncytial virus or influenza? |
| cord-344316-mwnnmwnw | -what's the future? |
| cord-354818-yf5lvbs1 | Should professionals caring for children be vaccinated? |
| cord-266204-ipa017wz | * 03-bound measles virus peptides by 2D- liquid chromatography tandem mass spectrometry Are cases of mumps in vaccinated patients attributable to mismatches in both vaccine T- cell and B- cell epitopes?: |
| cord-266204-ipa017wz | : how much can the adaptive immune system adapt? |
| cord-266204-ipa017wz | Is science leading us toward a new path of directed vaccine development and discovery? |
| cord-266204-ipa017wz | The immunogenetics of smallpox vaccination Genetic basis for adverse events after smallpox vaccination Identification of fever and vaccine- associated gene interaction networks using ontology- based literature mining Common variants associated with general and MMR vaccine- related febrile seizures The clinician's guide to the anti- vaccinationists'galaxy Trends affecting the future of vaccine development and delivery: the role of demographics, regulatory science, the anti- vaccine and consumer culture and vaccinomics Understanding those who do not understand: a brief review of the anti- vaccine movement Accelerated mass production of influenza virus seed stocks in HEK-293 suspension cell cultures by reverse genetics Cell culture- based influenza vaccines: A necessary and indispensable investment for the future Ebola virus vaccines: where do we stand? |
| cord-266204-ipa017wz | We have asked the question, as have other scientists,''does it make sense in the 21st century to give the same vaccine, dose, and at the same frequency to everyone, regardless of age, weight, gender, race, genotype, and medical condition?" |
| cord-336730-hqgwj8vs | Young cats are especially prone: 54% of all FIP cases affected cats younger than 12 months of age and 70% cats younger than 4 year?. |
| cord-299323-riotkgj4 | An Implementation Guide Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmacueticals? |
| cord-299323-riotkgj4 | What are the implications of this difference? |
| cord-299323-riotkgj4 | What is a Package Leaflet-How to review it? |
| cord-342831-4qfe8kok | The safety of chitosan as a pharmaceutical excipient Chitosan- based drug nanocarriers: where do we stand? |
| cord-322505-6q92742u | We use a mathematical model to address the following specific questions:( 1) can a RTV autonomously eradicate and/or protect a population that has previously experienced vector infection? |
| cord-322505-6q92742u | and( 2) if autonomous vaccination by a RTV is impossible, can augmenting the vaccine with direct, manual vaccinations make a RTV an effective tool for the control of infectious disease? |
| cord-252293-8286lsof | a systematic review and metaanalysis Is statin use associated with reduced mortality after pneumonia? |
| cord-294302-hboc3xcz | In vitro evaluation of antiviral and virucidal activity of a high molecular weight hyaluronic acid CD44 is the principal cell surface receptor for hyaluronate Renin- angiotensin system: the unexpected flaw inside the human immune system revealed by SARS- CoV-2 Type 1/ Type 2 immunity in infectious diseases Lymphopenia is associated with severe coronavirus disease 2019( COVID-19) infections: a systemic review and meta- analysis Signals of Th2 immune response from COVID-19 patients requiring intensive care The « moonlighting protein » able to explain the Th1 immune lockdown in severe COVID-19 Type 3 hypersensitivity in COVID-19 vasculitis What about the original antigenic sin of the humans versus SARS- CoV-2? |
| cord-294302-hboc3xcz | promotes cross- priming and Th1 immunity Propionibacterium acnes vaccination induces regulatory T cells and Th1 immune responses and improves mouse atopic dermatitis Innate, antigen- independent role for T cells in the activation of the immune system by Propionibacterium acnes BCG- induced trained immunity: can it offer protection against COVID-19? |
| cord-294302-hboc3xcz | title: COVID-19 vaccine and boosted immunity: nothing ad interim to do? |
| cord-263443-m98qisld | A cross- sectional analysis of UK telephone survey data When a COVID-19 vaccine is ready, will we all be ready for it? |
| cord-263443-m98qisld | Covid-19: What do we know so far about a vaccine? |
| cord-263443-m98qisld | The French public's attitudes to a future COVID-19 426 vaccine: the politicization of a public health issue Preparing for a COVID-19 vaccine: Identifying and 428 psychologically profiling those who are vaccine hesitant or resistance in two general population 429 samples Low acceptability of A/ H1N1 431 pandemic vaccination in french adult population: Did public health policy fuel public 432 dissonance? |
| cord-263443-m98qisld | followed by an open- ended question"Why?"or"Why not?" |
| cord-263443-m98qisld | followed by an open- ended question"Why?"or"Why not?" |
| cord-265757-8ces57rn | : leucocytosis explained? |
| cord-265757-8ces57rn | How best to estimate the global burden of pertussis? |
| cord-265757-8ces57rn | The lymphocytosis explained? |
| cord-313911-lfn9ggg3 | Smallpox vaccination: risk considerations for patients with atopic dermatitis Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines Identification of murine poxvirus- specific CD8+ CTL epitopes with distinct functional profiles Profiling the humoral immune response to infection by using proteome microarrays: high- throughput vaccine and diagnostic antigen discovery Smallpox vaccine- induced antibodies are necessary and sufficient for protection against monkeypox virus smallpox vaccinations: how much protection remains? |
| cord-313911-lfn9ggg3 | The future of smallpox vaccination: is MVA the key? |
| cord-270910-xb746mv5 | The second question asked about influenza vaccination nasal spray:''During the past 12 months,{ have you/ has NAME} had a flu vaccine sprayed in{ your/ his/ her}[ 26] nose by a doctor or other health professional? cord-270910-xb746mv5 An assessment of parental knowledge, attitudes, and beliefs regarding influenza vaccination What is'confidence'and what could affect it?: cord-270910-xb746mv5 During the past 12 months,{ have you/ has NAME} had a flu shot? cord-328698-eeg1k5a6 Have you ever postponed a vaccine recommended by a physician because of doubts about it?" |
| cord-328698-eeg1k5a6 | Once we have it, will we use it? |
| cord-328698-eeg1k5a6 | We evaluated participants'self- reported vaccine hesitancy according to the WHO definition using three previously adapted questions:"Have you ever refused a vaccine for yourself or a child because you considered it as useless or dangerous?" |
| cord-340686-uq0fsqh3 | Inhibition of herpes simplex virus multiplication by activated macrophages: a role for arginase? |
| cord-340686-uq0fsqh3 | l- Arginine deprivation impairs Leishmania major- specific T- cell responses Delivery systems: a vaccine strategy for overcoming mucosal tolerance? |
| cord-345191-nabxpyw3 | A European 619 survey on willingness to be vaccinated against COVID-19 Determinants of COVID-19 Vaccine 622 Acceptance in the Willingness to vaccinate against COVID-19 in Australia More vaccines for children? |
| cord-345191-nabxpyw3 | The push for a COVID-19 vaccine Millions could be vaccinated against COVID-19 as UK secures strong 606 portfolio of promising vaccines Ensuring global access to COVID-19 vaccines JCVI: updated interim advice on priority groups for COVID-19 610 vaccination Using thematic analysis in psychology Parents'and guardians'views on the acceptability of a future COVID-19 vaccine: a multi Sabat, I, Once we have it, will we use it? |
| cord-345191-nabxpyw3 | would you accept the vaccine for your child/ children?". |
| cord-273065-peqz7okh | Could they drive greater ZIKV replication through antibody- dependent enhancement( ADE)? |
| cord-273065-peqz7okh | How can that be understood and controlled? |
| cord-273065-peqz7okh | The vaccine should elicit equal protection against the four DENV serotypes, which has been extremely difficult to achieve, in view of competition between strains and/or ADE of some strains: the question has been raised of whether it really is a must to develop tetravalent vaccines? |
| cord-273065-peqz7okh | What is the feasibility and what will be the cost of a necessary pre- vaccination screening? |
| cord-273065-peqz7okh | What will be the cost of implementing pre- vaccination screening? |
| cord-273065-peqz7okh | Whom to vaccinate in places where DENV seropositivity in 9 years of age turns out to be very low( only 10% in Singapore for example)? |
| cord-273065-peqz7okh | Why does severity of the disease, especially that of the postvaccination adverse events, vary with age? |
| cord-348218-wyy4rvqb | A framework for health professionals From social media to mainstream news: The information flow of the vaccine- autism controversy in the US, Canada, and the UK Vaccination communication strategies: What have we learned, and lost, in 200 years I approve this message: Effects of sponsorship, ad tone and reactance in 2008 presidential advertising National and DHB immunisation data Reinforcement or reactance? |
| cord-348218-wyy4rvqb | At the time of writing this article a billboard produced by the New Zealand anti- vaccination group Warnings About Vaccination Expectations( WAVES) was placed on Auckland's southern motorway posing the question''If you knew the ingredients in a vaccine would you RISK it?" |
| cord-348218-wyy4rvqb | Effects of equivalence framing on the perceived truth of political messages and the trustworthiness of politicians Helpful or harmful? |
| cord-348218-wyy4rvqb | The HPV vaccine and the media: How has the topic been covered and what are the effects on knowledge about the virus and cervical cancer? |
| cord-302222-9ad0fw6z | An interesting question is: who will pay for vaccination of feedlot cattle? |
| cord-302222-9ad0fw6z | Is the economic benefit there for the meat industry, and will vaccination reduce the cost of other preventive measures and testing or will vaccine costs simply be on top of other costs? |
| cord-302222-9ad0fw6z | One health: the importance of companion animal vector- borne diseases Arthropod- borne infectious diseases of the dog and cat Zoonoses Control in dogs How to eradicate canine rabies: a perspective of historical efforts Mass vaccination campaign against rabies: are dogs correctly protected? |
| cord-302222-9ad0fw6z | Since ground beef only contributes about one- third of human infections, how could vaccines be used as a means of reducing other sources of food contamination? |
| cord-302222-9ad0fw6z | The use of veterinary vaccines for prevention and control of Rift Valley fever: memorandum from a WHO/ FAO meeting ZH501-VSVRI: Is it still the best choice for vaccination against Rift Valley fever in Egypt? |
| cord-302222-9ad0fw6z | Will government agencies concerned with human health subsidize the cost, without empirical demonstration of a human health benefit? |
| cord-302222-9ad0fw6z | understanding the dual- host lifestyle of Lyme disease spirochaetes The emergence of Lyme disease Vaccines against Lyme disease: what happened and what lessons can we learn? |
| cord-302222-9ad0fw6z | what happens on the ground? |
| cord-345658-u9vgycib | An emergent poxvirus from humans and cattle in Rio de Janeiro State: Cantagalo virus may derive from Brazilian smallpox vaccine Vaccinia virus natural infections in Brazil: the good, the bad, and the ugly Bovine Vaccinia: insights into the disease in cattle Transmission of vaccinia virus and rationale for measures for prevention Poxvirus pathogenesis Poxvirus DNA replication MVA as a vector for vaccines against HIV-1 Biosafety aspects of modified vaccinia virus Ankara( MVA)-based vectors used for gene therapy or vaccination Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara( MVA)-based vectors Hazard characterization of modified vaccinia virus ankara vector: what are the knowledge gaps? |
| cord-345658-u9vgycib | Does the wild type virus establish a latent or persistent infection? |
| cord-345658-u9vgycib | Does the wild type virus replicate in the nucleus? |
| cord-345658-u9vgycib | How is the wild type virus normally transmitted? |
| cord-345658-u9vgycib | [ 39] 3.2 What is the natural host for the wild type virus? |
| cord-318407-uy0f7f2o | How must academic veterinary medicine adapt to prepare veterinarians to respond to these new needs? |
| cord-318407-uy0f7f2o | How will these changes alter the needs of society? |
| cord-318407-uy0f7f2o | Misleading media reporting? |
| cord-318407-uy0f7f2o | The general epidemiologist: is there a place in today's epidemiology? |
| cord-318407-uy0f7f2o | or do we? |
| cord-010266-elhgew3x | And indeed, is it ethical that a person in the vaccine- producing country should enjoy the benefits which have been won at the expense of the risk- taking of a person in less privileged circumstances? |
| cord-010266-elhgew3x | Are the conditions leading to infection and the challenge organisms relevant? |
| cord-010266-elhgew3x | Are the people in whom the vaccine is tested likely to respond in an immunologically equivalent manner when the history of the exposure of their immune systems to disease is dissimilar in many ways to a person of the Developed World? |
| cord-010266-elhgew3x | But how safe is safe? |
| cord-010266-elhgew3x | But is this the appropriate ethic? |
| cord-010266-elhgew3x | Does this mean that the rich should pay a high price for a vaccine and thus subsidize the provision of cheap vaccines to the poor? |
| cord-010266-elhgew3x | For example, is it possible to obtain the informed consent of a person who is illiterate and who does not understand the implications of something like a vaccine with which( s)he is totally unfamiliar? |
| cord-010266-elhgew3x | In the event that there is damage to an individual as a result of exposure to vaccine in a trial, what are the levels of compensation and who pays? |
| cord-010266-elhgew3x | Is it appropriate to use a technical fix when an almost cost- free change of behaviour will achieve the same effect? |
| cord-010266-elhgew3x | May not the society, in accepting the benefit of widespread vaccination, compensate those who suffer damage at a level communsurate with the damage? |
| cord-010266-elhgew3x | One might ask, to what extent is a prophylactic trial in the Developing World relevant to the circumstances prevalent in the Developed World? |
| cord-010266-elhgew3x | Or is it the job of the elected representatives of the people to act as purchaser on behalf of the poor and provide the vaccine manufacturer compensation through the tax system or other fiscal dispensation? |
| cord-010266-elhgew3x | The question which this poses is, do those who have opted against vaccination have the right to benefit from the expense and the risks of vaccine- induced damage accepted by those who have been vaccinated? |
| cord-010266-elhgew3x | Were the genes of that cell to be used to make a pharmaceutical to particularly benefit people in the Developed World, what sort of compensation should acrue to the source of the cell line from which the gene was obtained? |
| cord-010266-elhgew3x | and what are the limits by which we define consistency? |
| cord-010266-elhgew3x | and what is efficacious? |
| cord-276209-5999g9gp | -Could a vaccine be provided through a revised definition of a compassionate use mechanism in the highest risk subjects after signing waivers of responsibility and enhanced informed- consent procedures? |
| cord-276209-5999g9gp | -Might one conceive of differential regulatory pathways for vaccine candidates using well- understood antigens, vaccine methodology, adjuvants, manufacture, and routes of administration( TBD) versus those using novel delivery technology and novel antigens or adjuvants? |
| cord-276209-5999g9gp | -What will be the endpoint for determining vaccine efficacyprevention of infection? |
| cord-276209-5999g9gp | -What, if any, animal models might be developed that allow the''animal rule"to be utilized in an effort to accelerate research and licensure? |
| cord-276209-5999g9gp | Could this be a viable strategy in accelerating licensure? |
| cord-276209-5999g9gp | For example, what level of risk are we willing to tolerate to immunize against an infection that may disappear in the next year or two? |
| cord-276209-5999g9gp | I and II trials are conducted earlier than normal procedure, could a phased initiation of studies from highest risk to lowest risk subjects be utilized? |
| cord-276209-5999g9gp | Might reasonable''accommodations"be made for such a scenario? |
| cord-276209-5999g9gp | Might that safety profile be somewhat different( to be defined) in an exceptionally high risk 80-yearold with multiple co- morbidities? |
| cord-276209-5999g9gp | Or that could diminish in severity in the short- to mid- term? |
| cord-276209-5999g9gp | Or to administer to young children whose risk of both serious illness or death is quantifiably very, very low? |
| cord-276209-5999g9gp | Other?-Will |
| cord-276209-5999g9gp | Prevention of severe disease? |
| cord-276209-5999g9gp | Prevention of viral shedding? |
| cord-276209-5999g9gp | Several seem worth immediate discussion:-Could a vaccine be provided through an EUA mechanism for mentally competent adults who meet certain risk guidelines, and in the context of study enrollment and data collection, and enhanced informed consent? |
| cord-276209-5999g9gp | What about for pregnant women or younger but immunocompromised persons? |
| cord-276209-5999g9gp | What does history teach us in regard to vaccine development? |
| cord-276209-5999g9gp | Who should be included- perhaps healthcare providers and first responders who share the highest risk of infection as a starting point? |
| cord-276209-5999g9gp | different vaccines and different regulatory pathways be feasible for different members of the population with differing risk: benefit ratios? |
| cord-285128-48l1w65p | Are there antiviral or other treatments available for disease manifestations caused by the vaccine? |
| cord-285128-48l1w65p | Does an animal model for antibody enhanced disease or immune complex disease exist? |
| cord-285128-48l1w65p | Does an animal model for immunogenicity and efficacy exist? |
| cord-285128-48l1w65p | Does an animal model for reproductive toxicity exist? |
| cord-285128-48l1w65p | Does an animal model for safety including immuno- compromised animals exist? |
| cord-285128-48l1w65p | Does an animal model relevant to assess attenuation exist? |
| cord-285128-48l1w65p | Does the vaccine replicate in the nucleus? |
| cord-285128-48l1w65p | For replicating vectors, has a comparative virulence and viral kinetic study been conducted in permissive and susceptible species? |
| cord-285128-48l1w65p | How is the transgene expression controlled( transcriptional promoters, etc.)? |
| cord-285128-48l1w65p | If not, what species would be used for such a study? |
| cord-285128-48l1w65p | Is it feasible to conduct such a study? |
| cord-285128-48l1w65p | Is the vaccine replicationcompetent in humans or other species? |
| cord-285128-48l1w65p | Is the vaccine transmissible in humans or other species( including arthropods) and/or stable in the environment? |
| cord-285128-48l1w65p | Nonhuman primates( NHP)? |
| cord-285128-48l1w65p | Pregnancy and in the unborn in humans? |
| cord-285128-48l1w65p | Small animal models? |
| cord-285128-48l1w65p | What is known about biodistribution in animal models or in humans? |
| cord-285128-48l1w65p | What is known about the effect of pre- existing immunity, including both natural immunity and repeat administration of the vector or the vaccine, on'take', safety or efficacy in any animal model or human studies using this vector? |
| cord-285128-48l1w65p | What is known about the mechanisms of immunity to the vaccine? |
| cord-285128-48l1w65p | What is the potential for shedding and transmission in risk groups? |
| cord-285128-48l1w65p | What is the potential for shedding and transmission to humans or other species? |
| cord-285128-48l1w65p | What is the potential for shedding and transmission to humans or other species? |
| cord-285128-48l1w65p | What is the risk of integration into the human genome? |
| cord-285128-48l1w65p | What is the risk of reversion to virulence or recombination with wild type or other agents? |
| cord-285128-48l1w65p | What is the risk of reversion to virulence or recombination with wild type virus or other agents? |